Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Multicenter Retrospective Study) III

Aortic Dissection Clinical Trial

Official title:

Inflammatory Response and Anti-inflammatory Action for Aortopathy & Arteriopathy (5A-Plan): A Multicenter Retrospective Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04918108
• Other study ID #: 5A-Plan III
• Status: Completed
• Start date: January 1, 2021
• Est. completion date: August 30, 2021

Study information

• Verified date: October 2021
• Source: Nanjing Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Anatomopathological classifications have been well identified in aortic dissection with important therapeutic implications. The authors evaluated the inflammatory response in patients with aortic dissection (AD) and assessed the presence of distinct inflammatory subphenotypes within this disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2000
• Est. completion date: August 30, 2021
• Est. primary completion date: August 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• acute type Aortic dissection;

Exclusion Criteria:

• Iatrogenic aortic dissection OR traumatic aortic dissection
• Patients with hematological diseases, infectious diseases, malignant tumors, immune system diseases, or severe liver diseases.
• Preoperative use of mechanical ventilation, blood transfusion, renal replacement therapy, extracorporeal membrane oxygenation, or intra-aortic balloon pump during the current admission.

Related Conditions & MeSH terms

• Aneurysm, Dissecting
• Aortic Dissection

Intervention

Biological:
• inflammatory response
laboratory data (leukocyte, neutrophils, monocyte, lymphocytes, platelet, fibrinogen, D-dimer, neutrophils-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio)

Locations

Country	Name	City	State
China	The first affiliated hospital of nanjing medical university	Nanjing	Jiangsu

Sponsors (13)

Lead Sponsor

Collaborator

Nanjing Medical University

Beijing Anzhen Hospital, First Affiliated Hospital Bengbu Medical College, Nanjing First Hospital, Nanjing Medical University, Shanghai East Hospital Tongji University, TEDA International Cardiovascular Hospital, The Affiliated Hospital of Qingdao University, The First Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital of Shantou University Medical College, The First Affiliated Hospital with Nanjing Medical University, Tianjin Chest Hospital, Tianjin Medical University, Xiamen Cardiovascular Hospital, Xiangya Hospital of Central South University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	30-day mortality	any cause death within 30 days of surgery	30 days after surgery
Secondary	ICU mortality	any cause death within ICU	7 days after surgery